{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:37:11Z","timestamp":1785908231924,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Israel Cancer Association (R. A.)","award":["grants No. 20191644 and No. 20180071"],"award-info":[{"award-number":["grants No. 20191644 and No. 20180071"]}]},{"name":"The Israel Innovation Authority","award":["Incubator project that was granted to IDD Therapeutics, Ltd., between the years 2010-2014"],"award-info":[{"award-number":["Incubator project that was granted to IDD Therapeutics, Ltd., between the years 2010-2014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Paclitaxel-lipoate (IDD-1040) is a conjugate formed by the chemical joining of the two compounds, by condensing a lipoic acid moiety to the C2\u2032 of paclitaxel. IDD-1040 was evaluated for its anti-tumor activity and potential druggability, using an in vivo non-small-cell, lung cancer (NSCLC) xenograft mouse model. In the in vivo studies, IDD-1040 showed a maximum tolerated dose (MTD) of 250 mg\/kg compared to paclitaxel (PTX), with an MTD of 20 mg\/kg. Most interesting, IDD-1040 demonstrated higher anti-tumor activity, and its inhibitory activity on tumor volume (cell growth) was dose-dependent. That anti-tumor activity persisted for two weeks after cessation of IDD-1040 treatment, as opposed to PTX cessation, after which the tumor relapsed, confirming that IDD-1040 exhibits superior tumor inhibition. Similar to PTX treatment, no marked body weight decrease was observed during IDD-1040 treatment, indicating a low toxicity profile. The increase in animal body weight noted over time was due to the increasing weight of tumors, recorded in all the mouse test groups. The results also showed that mortality rate of mice was reduced by treatment with IDD-1040, more so than with PTX. Furthermore, in a preliminary study on the ex vivo distribution of IDD-1040, neutropenia was primarily concentrated in the liver 1 h after injection, and most of the drug was metabolized by the liver in 24 h. All of these results demonstrate IDD-1040\u2019s great potential as a candidate drug for cancer treatment.<\/jats:p>","DOI":"10.3390\/ijms20194965","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T03:14:33Z","timestamp":1570590873000},"page":"4965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Novel Paclitaxel Conjugate with Higher Efficiency and Lower Toxicity: A New Drug Candidate for Cancer Treatment"],"prefix":"10.3390","volume":"20","author":[{"given":"Mizied","family":"Falah","sequence":"first","affiliation":[{"name":"Institute for Medical Research, Galilee Medical Center, Nahariya 2210001, Israel"},{"name":"Faculty of Medicine in the Galilee, Bar-Ilan University, Safed 1311502, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Rayan","sequence":"additional","affiliation":[{"name":"Drug Discovery Informatics Lab, QRC\u2014Qasemi Research Center, Al-Qasemi Academic College, Baka El-Garbiah 30100, Israel"},{"name":"HydroMap Limited Company, Kabul 2496300, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Rayan","sequence":"additional","affiliation":[{"name":"Drug Discovery Informatics Lab, QRC\u2014Qasemi Research Center, Al-Qasemi Academic College, Baka El-Garbiah 30100, Israel"},{"name":"Institute of Applied Research, Galilee Society, Shefa-Amr 20200, Israel"},{"name":"IDD Therapeutics, Wadi El-Haj 13, P.O. Box 1252, Nazareth 17111, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","article-title":"Taxol: A novel investigational antimicrotubule agent","volume":"82","author":"Rowinsky","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_2","first-page":"3601","article-title":"2\u2019-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model","volume":"9","author":"Peng","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2016.02.011","article-title":"A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes","volume":"141","author":"Mabuchi","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2017.06.013","article-title":"Paclitaxel loaded phospholipid-based gel as a drug delivery system for local treatment of glioma","volume":"528","author":"Chen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","article-title":"Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"146","author":"Cohn","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","article-title":"Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives","volume":"50","author":"Schettini","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2015.02.024","article-title":"Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: Preparation, in vitro and in vivo evaluation","volume":"208","author":"He","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1111\/j.1742-4658.2009.06994.x","article-title":"Possible binding site for paclitaxel at microtubule pores","volume":"276","author":"Magnani","year":"2009","journal-title":"FEBS J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(02)00109-9","article-title":"Weekly administration of paclitaxel: Theoretical and clinical basis","volume":"44","author":"Marchetti","year":"2002","journal-title":"Crit. Rev. Oncol Hematol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025513106330","article-title":"Microtubules, microtubule-interfering agents and apoptosis","volume":"8","author":"Mollinedo","year":"2003","journal-title":"Apoptosis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/iub.25","article-title":"Microtubules: A dynamic target in cancer therapy","volume":"60","author":"Pasquier","year":"2008","journal-title":"IUBMB Life"},{"key":"ref_14","first-page":"1253","article-title":"Taxol induces bcl-2 phosphorylation and death of prostate cancer cells","volume":"56","author":"Haldar","year":"1996","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ctrv.2015.02.003","article-title":"Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials","volume":"41","author":"Carbognin","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.01.049","article-title":"Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (beta-amino ester) nanoparticles co-delivering two siRNA and paclitaxel","volume":"48","author":"Tang","year":"2015","journal-title":"Biomaterials"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-014-2607-5","article-title":"Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer","volume":"75","author":"Rivera","year":"2015","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1634\/theoncologist.4-5-408","article-title":"Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer","volume":"4","author":"Socinski","year":"1999","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J. Am. Chem. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.freeradbiomed.2010.01.018","article-title":"Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress","volume":"48","author":"Hadzic","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_22","first-page":"289","article-title":"Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases","volume":"8","author":"Ricciardi","year":"2015","journal-title":"Oncol. Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/0300060518756540","article-title":"Effect of alpha-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy","volume":"46","author":"Agathos","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_24","first-page":"2893","article-title":"Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2","volume":"37","author":"Wozniak","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17934","DOI":"10.4238\/2015.December.22.18","article-title":"Effect of lipoic acid combined with paclitaxel on breast cancer cells","volume":"14","author":"Li","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0014-5793(95)01489-6","article-title":"Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid","volume":"379","author":"Whiteman","year":"1996","journal-title":"FEBS Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/03602539808996311","article-title":"alpha-Lipoic acid: A metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury","volume":"30","author":"Packer","year":"1998","journal-title":"Drug Metab Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1093\/jn\/133.11.3327","article-title":"Alpha-lipoic acid and cardiovascular disease","volume":"133","author":"Wollin","year":"2003","journal-title":"J. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.fct.2011.07.065","article-title":"Alpha-lipoic acid protects against myocardial ischemia\/reperfusion injury via multiple target effects","volume":"49","author":"Wang","year":"2011","journal-title":"Food Chem. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ambrosi, N., Guerrieri, D., Caro, F., Sanchez, F., Haeublein, G., Casadei, D., Incardona, C., and Chuluyan, E. (2018). Alpha Lipoic Acid: A Therapeutic Strategy that tend to Limit the Action of Free Radicals in Transplantation. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010102"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1517\/14656566.2014.972935","article-title":"Efficacy of alpha-lipoic acid in diabetic neuropathy","volume":"15","author":"Papanas","year":"2014","journal-title":"Expert Opin. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2337\/diacare.22.8.1296","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy","volume":"22","author":"Ziegler","year":"1999","journal-title":"Diabetes Care"},{"key":"ref_34","first-page":"343","article-title":"The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects","volume":"12","author":"Carlson","year":"2007","journal-title":"Altern Med. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/17512433.2014.966816","article-title":"Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy","volume":"7","author":"Bingham","year":"2014","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_36","first-page":"611","article-title":"Chemopreventive potential of alpha lipoic acid in the treatment of colon and cervix cancer cell lines","volume":"115","author":"Damnjanovic","year":"2014","journal-title":"Bratisl. Lek. Listy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbrc.2017.10.030","article-title":"alpha-Lipoic acid inhibits human lung cancer cell proliferation through Grb2-mediated EGFR downregulation","volume":"494","author":"Yang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","first-page":"460","article-title":"Phthalate induced toxicity in prostate cancer cell lines and effects of alpha lipoic acid","volume":"118","author":"Kismali","year":"2017","journal-title":"Bratisl. Lek. Listy"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:28:23Z","timestamp":1760189303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":38,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["ijms20194965"],"URL":"https:\/\/doi.org\/10.3390\/ijms20194965","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]}}}